Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 11/20 | 0.48 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 4/20 | 0.37 |
| ▸ | MMP1 | P03956 | 3/20 | 0.37 |
| ▸ | MMP3 | P08254 | 3/20 | 0.37 |
| ▸ | MMP7 | P09237 | 3/20 | 0.37 |
| ▸ | MMP9 | P14780 | 3/20 | 0.37 |
| ▸ | MMP8 | P22894 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742710 | 0.92 | STS (0.51) | STSELOVL6HRH1CCR3MMP13 | |
| SCHEMBL8089162 | 0.85 | STS (0.50) | STSELOVL6HRH1CCR3CACNA1B | |
| SCHEMBL13045261 | 0.83 | GAA (0.44) | STSCACNA1BKMT2A | |
| SCHEMBL3751310 | 0.76 | GPR119 (0.42) | — | |
| SCHEMBL8079018 | 0.76 | CHRM1 (0.54) | — | |
| SCHEMBL894936 | 0.73 | CHRM2 (0.38) | KMT2A | |
| SCHEMBL10026719 | 0.73 | CHRM2 (0.38) | KMT2A | |
| SCHEMBL3752853 | 0.72 | ALDH1A1 (0.39) | MMP13 | |
| SCHEMBL3748764 | 0.72 | CTSL (0.50) | KMT2A | |
| SCHEMBL3744365 | 0.72 | CTSL (0.50) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | STS 2135/4885ELOVL6 1589/4885HRH1 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.